MDGL — Madrigal Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $4.05bn
- $3.54bn
- 43
- 13
- 57
- 31
Annual cashflow statement for Madrigal Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -83.9 | -202 | -242 | -295 | -374 |
| Depreciation | |||||
| Non-Cash Items | 22.8 | 20.7 | 26.9 | 32.4 | 52.1 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 19.5 | 23.5 | 30.7 | 37.6 | -3.28 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -41.6 | -158 | -184 | -225 | -324 |
| Capital Expenditures | -0.172 | -0.334 | -0.209 | -0.217 | -1.48 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 30.9 | 160 | -4.85 | 207 | -501 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 30.7 | 160 | -5.05 | 207 | -503 |
| Financing Cash Flow Items | — | — | — | -0.886 | -0.363 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.235 | 5.09 | 171 | 313 | 595 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.7 | 7.31 | -17.7 | 295 | -232 |